Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance

    NCT04062890 · start 2030-04-15

    Registered record
    Registry ID
    NCT04062890
    Conditions
    Hyperinsulinism; Insulin Resistance; Insulin Sensitivity; Glucose Intolerance; Hypertension
    Interventions
    Vigabatrin Pill; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2030-04-15
    Completion
    2030-12-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperinsulinism; Insulin Resistance; Insulin Sensitivity; Glucose Intolerance +1 more
    InterventionVigabatrin Pill; Placebo oral tablet
    PhasePhase 2
    Registry statusWithdrawn

  • EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS

    NCT07626099 · start 2028-06-30

    Registered record
    Registry ID
    NCT07626099
    Conditions
    Allergic Rhinitis (AR)
    Interventions
    AYURVEDA treatment protocol; Control(Citrizine 10mg)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2028-06-30
    Completion
    2030-12-30
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis (AR)
    InterventionAYURVEDA treatment protocol; Control(Citrizine 10mg)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)

    NCT05085808 · start 2028-03-01

    Registered record
    Registry ID
    NCT05085808
    Conditions
    Delirium; Morality; Quality of Life; Psych; Treatment Side Effects
    Interventions
    Trazodone; Quetiapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2028-03-01
    Completion
    2030-12-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Morality; Quality of Life; Psych +1 more
    InterventionTrazodone; Quetiapine; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Effectiveness of Non-surgical Management in Rotator Cuff Calcific Tendinopathy (THE EFFECT TRIAL)

    NCT05478902 · start 2028-01-01

    Registered record
    Registry ID
    NCT05478902
    Conditions
    Rotator Cuff Tendinosis; Rotator Cuff Injuries; Shoulder Tendinitis; Calcific Shoulder Tendinitis; Calcification Tendon; Calcific Tendinitis; Shoulder Pain
    Interventions
    Exercise Therapy; Extracorporeal Shockwave Therapy; Ultrasound-Guided Percutaneous Irrigation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Suspended
    Start
    2028-01-01
    Completion
    2029-12-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRotator Cuff Tendinosis; Rotator Cuff Injuries; Shoulder Tendinitis; Calcific Shoulder Tendinitis +3 more
    InterventionExercise Therapy; Extracorporeal Shockwave Therapy; Ultrasound-Guided Percutaneous Irrigation
    PhaseNot applicable
    Registry statusSuspended

  • Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial

    NCT07639528 · start 2027-12-10

    Registered record
    Registry ID
    NCT07639528
    Conditions
    Resectable Intrahepatic Cholangiocarcinoma
    Interventions
    Biospecimen Collection; Cisplatin; Computed Tomography; Durvalumab; Futibatinib; Gemcitabine; Magnetic Resonance Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-12-10
    Completion
    2031-12-10
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResectable Intrahepatic Cholangiocarcinoma
    InterventionBiospecimen Collection; Cisplatin; Computed Tomography; Durvalumab +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

    NCT06752876 · start 2027-12

    Registered record
    Registry ID
    NCT06752876
    Conditions
    Systemic Lupus Erythematosus; Lupus; Lupus Erythematosus; Lupus Nephritis
    Interventions
    CB-010
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2027-12
    Completion
    2029-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus; Lupus; Lupus Erythematosus; Lupus Nephritis
    InterventionCB-010
    PhasePhase 1
    Registry statusWithdrawn

  • Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.

    NCT05931484 · start 2027-11-01

    Registered record
    Registry ID
    NCT05931484
    Conditions
    Parkinson Disease
    Interventions
    Gemfibrozil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2027-11-01
    Completion
    2028-11-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionGemfibrozil; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

    NCT07742553 · start 2027-10-01

    Registered record
    Registry ID
    NCT07742553
    Conditions
    Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord; Spinal Cord Contusion; Spinal Cord Trauma; Trauma, Nervous System; Wounds and Injuries; Spinal Cord Compression; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male
    Interventions
    testosterone cypionate; finasteride; placebo injection; placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-10-01
    Completion
    2032-03-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord; Spinal Cord Contusion +10 more
    Interventiontestosterone cypionate; finasteride; placebo injection; placebo pill
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Terazosin for Dementia With Lewy Bodies

    NCT04760860 · start 2027-10

    Registered record
    Registry ID
    NCT04760860
    Conditions
    Dementia With Lewy Bodies
    Interventions
    Terazosin Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-10
    Completion
    2030-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia With Lewy Bodies
    InterventionTerazosin Hydrochloride; Placebo
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Dantrolene in Statin-induced Myopathy

    NCT06966843 · start 2027-10

    Registered record
    Registry ID
    NCT06966843
    Conditions
    Statins Induced Myopathy
    Interventions
    Dantrolene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-10
    Completion
    2030-03
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStatins Induced Myopathy
    InterventionDantrolene; Placebo
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease

    NCT07553377 · start 2027-10

    Registered record
    Registry ID
    NCT07553377
    Conditions
    Alcohol Use Disorder; Alcohol Associated Liver Disease; Medications for Alcohol Use Disorder; Behavioral Medicine; Medication Adherence
    Interventions
    AcamproSync
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2027-10
    Completion
    2030-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder; Alcohol Associated Liver Disease; Medications for Alcohol Use Disorder; Behavioral Medicine +1 more
    InterventionAcamproSync
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    NCT07594548 · start 2027-09-09

    Registered record
    Registry ID
    NCT07594548
    Conditions
    Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Esophageal Adenocarcinoma; Locally Advanced Gastric Adenocarcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Carcinoma
    Interventions
    Biospecimen Collection; Computed Tomography; Futibatinib; Magnetic Resonance Imaging; Paclitaxel; Ramucirumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2027-09-09
    Completion
    2031-09-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 +12 more
    InterventionBiospecimen Collection; Computed Tomography; Futibatinib; Magnetic Resonance Imaging +2 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

    NCT05217498 · start 2027-09-01

    Registered record
    Registry ID
    NCT05217498
    Conditions
    Spinal Cord Injuries; Myelopathy
    Interventions
    Istradefylline; low oxygen therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-09-01
    Completion
    2028-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injuries; Myelopathy
    InterventionIstradefylline; low oxygen therapy
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Terazosin And Metabolic Engagement in Alzheimer's Disease

    NCT07796308 · start 2027-08-01

    Registered record
    Registry ID
    NCT07796308
    Conditions
    Alzheimer s Disease
    Interventions
    Terazosin (Hytrin); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-08-01
    Completion
    2032-07-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer s Disease
    InterventionTerazosin (Hytrin); Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone

    NCT05948579 · start 2027-08

    Registered record
    Registry ID
    NCT05948579
    Conditions
    Post Traumatic Stress Disorder
    Interventions
    Intervention B Vilazodone Hydrochloride (HCl); Intervention B Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-08
    Completion
    2028-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Traumatic Stress Disorder
    InterventionIntervention B Vilazodone Hydrochloride (HCl); Intervention B Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.